Tidepath

Growth-hormone peptides

CJC-1295 with DAC

The same peptide with an add-on that keeps it in the blood for days.

Status
Not approved by the FDA.
Routes we have on file
By injection
Where doses come from
No checked dose range
Half-life
About 5.8-8.1 days

What it is

CJC-1295 with DAC has an add-on, a drug affinity complex (DAC), that attaches it to albumin, a protein in the blood. Studies in people measured it staying in circulation for days. It acts on the same receptor as the form without DAC, for a very different length of time.

What makes it distinct

Its half-life, the time it takes for half a dose to clear, is 5.8 to 8.1 days. It was measured in studies in people, so it comes from trials rather than from people's reports. That covers the half-life only. It doesn't give a dose Tidepath could check. The FDA says it has identified serious health problems (serious adverse events) linked to CJC-1295. They include a faster heart rate and blood vessels widening throughout the body (systemic vasodilatory reaction). Its note doesn't say where it found them, or which form of CJC-1295 it means. It also says compounded CJC-1295 (mixed from its ingredients by a pharmacist or doctor) given certain ways may carry a risk of immune reactions (immunogenicity). It adds that impurities related to the peptide, and checking what the ingredient is, may be complicated, and that clinical data are limited.

Open questions

  • How a fixed amount compares with the weight-based doses that were studied.
  • Whether stimulating the receptor steadily for days has different effects from the form without DAC. In one study in healthy men, growth hormone still came in bursts (pulsatile release) a week after a dose, with higher levels between bursts.

More in Growth-hormone peptides